Pyxis Oncology, Inc. (PYXS): Cost of Revenue
$2.39M
Year ended 2025-12-31
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.39M | +402.7% | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | $475.0K | n/a | 2026-03-23, From 2024-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $2.39M | +402.7% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $7.04M | -17.6% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.64M | -14.5% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $857.0K | -28.6% |
| uniQure N.V. (QURE) | 2025-12-31 | $1.69M | +33.1% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $3.77M | +93.0% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $4.62M | +20.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $10.64M | -38.8% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.03M | +7.1% |
Compare PYXS, CVSI, TNXP, EMMA side by side · Screen every company in Pharmaceutical Preparations ↗